Bree B Aldridge

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8251718/publications.pdf

Version: 2024-02-01

37 papers	3,632 citations	304743 22 h-index	330143 37 g-index
46 all docs	46 docs citations	46 times ranked	4765 citing authors

#	Article	IF	Citations
1	Definitions and guidelines for research on antibiotic persistence. Nature Reviews Microbiology, 2019, 17, 441-448.	28.6	748
2	Physicochemical modelling of cell signalling pathways. Nature Cell Biology, 2006, 8, 1195-1203.	10.3	558
3	Asymmetry and Aging of Mycobacterial Cells Lead to Variable Growth and Antibiotic Susceptibility. Science, 2012, 335, 100-104.	12.6	411
4	Quantitative Analysis of Pathways Controlling Extrinsic Apoptosis in Single Cells. Molecular Cell, 2008, 30, 11-25.	9.7	357
5	Misorientation and reduced stretching of aligned sister kinetochores promote chromosome missegregation in EB1- or APC-depleted cells. EMBO Journal, 2006, 25, 2814-2827.	7.8	150
6	Fuzzy Logic Analysis of Kinase Pathway Crosstalk in TNF/EGF/Insulin-Induced Signaling. PLoS Computational Biology, 2009, 5, e1000340.	3.2	145
7	Engineered cell and tissue models of pulmonary fibrosis. Advanced Drug Delivery Reviews, 2018, 129, 78-94.	13.7	108
8	Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis. Science Advances, 2017, 3, e1701881.	10.3	107
9	Exploitation of Mycobacterium tuberculosis Reporter Strains to Probe the Impact of Vaccination at Sites of Infection. PLoS Pathogens, 2014, 10, e1004394.	4.7	78
10	Spatially distinct and metabolically active membrane domain in mycobacteria. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5400-5405.	7.1	78
11	Microbial metabolomics: innovation, application, insight. Current Opinion in Microbiology, 2014, 19, 90-96.	5.1	65
12	Lyapunov exponents and phase diagrams reveal multiâ€factorial control over TRAILâ€induced apoptosis. Molecular Systems Biology, 2011, 7, 553.	7.2	62
13	A Parallel Adder Coordinates Mycobacterial Cell-Cycle Progression and Cell-Size Homeostasis in the Context of Asymmetric Growth and Organization. Current Biology, 2017, 27, 3367-3374.e7.	3.9	62
14	Stress-Induced Reorganization of the Mycobacterial Membrane Domain. MBio, 2018, 9, .	4.1	50
15	Protein Complexes and Proteolytic Activation of the Cell Wall Hydrolase RipA Regulate Septal Resolution in Mycobacteria. PLoS Pathogens, 2013, 9, e1003197.	4.7	49
16	Influence of Stress and Antibiotic Resistance on Cell-Length Distribution in Mycobacterium tuberculosis Clinical Isolates. Frontiers in Microbiology, 2017, 8, 2296.	3.5	49
17	Prediction of ultra-high-order antibiotic combinations based on pairwise interactions. PLoS Computational Biology, 2019, 15, e1006774.	3.2	49
18	Temporal and intrinsic factors of rifampicin tolerance in mycobacteria. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8302-8307.	7.1	44

#	Article	IF	Citations
19	Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis. MBio, 2019, 10, .	4.1	37
20	The Tuberculosis Drug Accelerator at year 10: what have we learned?. Nature Medicine, 2021, 27, 1333-1337.	30.7	32
21	Systematic measurement of combination-drug landscapes to predict inÂvivo treatment outcomes for tuberculosis. Cell Systems, 2021, 12, 1046-1063.e7.	6.2	31
22	Morphological profiling of tubercle bacilli identifies drug pathways of action. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18744-18753.	7.1	27
23	Polar assembly and scaffolding proteins of the virulenceâ€associated ESXâ€1 secretory apparatus in mycobacteria. Molecular Microbiology, 2012, 83, 654-664.	2.5	26
24	Stable Regulation of Cell Cycle Events in Mycobacteria: Insights From Inherently Heterogeneous Bacterial Populations. Frontiers in Microbiology, 2018, 9, 514.	3.5	26
25	The Spectrum of Drug Susceptibility in Mycobacteria. Microbiology Spectrum, 2014, 2, .	3.0	24
26	Rv0004 is a new essential member of the mycobacterial DNA replication machinery. PLoS Genetics, 2017, 13, e1007115.	3.5	21
27	Identification of cell wall synthesis inhibitors active against Mycobacterium tuberculosis by competitive activity-based protein profiling. Cell Chemical Biology, 2022, 29, 883-896.e5.	5.2	20
28	Types and functions of heterogeneity in mycobacteria. Nature Reviews Microbiology, 2022, 20, 529-541.	28.6	19
29	Setting Our Sights on Infectious Diseases. ACS Infectious Diseases, 2020, 6, 3-13.	3.8	17
30	Accelerating Early Antituberculosis Drug Discovery by Creating Mycobacterial Indicator Strains That Predict Mode of Action. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	15
31	Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits. Antimicrobial Agents and Chemotherapy, 2021, 65, e0002421.	3.2	12
32	Efficient Measurement of Drug Interactions with DiaMOND (Diagonal Measurement of N-Way Drug) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	6.9	10
33	Targeting drugs for tuberculosis. Science, 2019, 364, 1234-1235.	12.6	7
34	Leveraging laboratory and clinical studies to design effective antibiotic combination therapy. Current Opinion in Microbiology, 2021, 64, 68-75.	5.1	7
35	Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mclâ€1 Inhibitor AZD5991. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 561-570.	2.5	1
36	Localization of EccA3 at the growing pole in Mycobacterium smegmatis. BMC Microbiology, 2022, 22, 140.	3.3	1

#	Article	IF	Citations
37	The Spectrum of Drug Susceptibility in Mycobacteria. , 0, , 709-725.		0